| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
BATCP targets the enzymatic activities of histone deacetylase 6 (HDAC6) and sirtuin 1 (SIRT1). HDAC6 is a class IIb histone deacetylase that primarily deacetylates cytoplasmic proteins such as α-tubulin and cortactin, playing important roles in cell motility, protein degradation, and the immune response. SIRT1 is a NAD+-dependent deacetylase that regulates metabolism, inflammation, and longevity. BATCP serves as a substrate for these enzymes, enabling the measurement of their catalytic activity through the release of a fluorescent product.
|
|---|---|
| ln Vitro |
As a substrate rather than an inhibitor, BATCP itself does not possess inhibitory activity against HDAC6 or SIRT1. Its utility lies in its ability to be cleaved by these enzymes, releasing the fluorescent AFC moiety. The compound is used in enzymatic assays to measure HDAC6 and SIRT1 activity, with the rate of fluorescence increase being proportional to enzyme activity. BATCP is not evaluated for traditional in vitro activity such as IC50 values against cell lines, as it is a detection reagent rather than a therapeutic compound.
|
| ln Vivo |
BATCP is not a therapeutic compound and is not evaluated for in vivo activity in the traditional sense. Its primary application is in biochemical assays for measuring HDAC6 and SIRT1 activity in vitro. However, the compound could potentially be used in ex vivo assays to measure enzyme activity in tissue lysates or in imaging applications to visualize HDAC6 or SIRT1 activity in live cells or tissues.
|
| Enzyme Assay |
Non-cell-based enzyme assays with BATCP typically involve incubating the substrate with purified HDAC6 or SIRT1 enzyme in an appropriate buffer system. A standard protocol includes: preparing a reaction buffer (pH 8.0 for HDAC6 or pH 7.5 for SIRT1 with NAD+), adding BATCP at concentrations ranging from 1 to 100 μM, initiating the reaction by adding the enzyme, and incubating at 37°C for 30–60 minutes. The reaction is stopped by adding a stop solution (e.g., 10 mM nicotinamide for SIRT1 or an HDAC inhibitor), and fluorescence is measured at excitation/emission wavelengths of 400/505 nm for AFC.
|
| Cell Assay |
Cell-based assays with BATCP are typically performed using cell lysates or live cells expressing HDAC6 or SIRT1. A representative protocol for cell lysate assays includes: lysing cells in a suitable buffer, incubating the lysate with BATCP at 37°C for 1–2 hours, and measuring fluorescence at 400/505 nm. For live-cell imaging, cells are incubated with BATCP (typically 10–50 μM) for 1–4 hours, and fluorescence is monitored using a fluorescence microscope or plate reader. The compound's cell permeability enables its use in live-cell applications, although the substrate is primarily designed for biochemical assays.
|
| Animal Protocol |
In vivo animal studies with BATCP are not typically conducted as the compound is a research substrate rather than a therapeutic agent. However, the compound could potentially be used in animal models to assess HDAC6 or SIRT1 activity in tissues following administration. A typical protocol for such studies might involve intravenous or intraperitoneal injection of BATCP, followed by tissue harvest and fluorescence measurement to assess enzyme activity in specific organs. The compound is not intended for therapeutic development and is used exclusively as a research tool.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not typically evaluated for BATCP as it is a research substrate rather than a therapeutic compound. The compound is designed for use in biochemical and cell-based assays to measure enzyme activity. BATCP is soluble in DMSO at 16 mg/mL and is typically stored as a powder at -20°C for long-term preservation. For use in assays, the compound is dissolved in DMSO and diluted in aqueous buffer.
|
| Toxicity/Toxicokinetics |
As a research substrate, BATCP is not intended for human therapeutic use, and comprehensive toxicological data are not available. Standard laboratory safety precautions should be followed when handling the compound. The compound is typically stored at -20°C in a sealed container, protected from moisture and light. BATCP is not classified as a hazardous substance for routine laboratory use, but appropriate personal protective equipment should be worn during handling.
|
| References | |
| Additional Infomation |
BATCP (CAS 787549-23-9, also known as a fluorogenic HDAC6/SIRT1 substrate) is a valuable research tool for studying the enzymatic activities of HDAC6 and SIRT1. Upon enzymatic cleavage, the release of AFC enables sensitive and quantitative detection of enzyme activity using fluorescence spectroscopy. This substrate is widely used in high-throughput screening campaigns to identify inhibitors of HDAC6 and SIRT1, as well as in basic research to study the regulation of these enzymes in various biological contexts. BATCP is available in high purity (>99%) and is suitable for a variety of assay formats.
|
| Molecular Formula |
C23H28F3N3O6
|
|---|---|
| Molecular Weight |
499.48
|
| Exact Mass |
499.193
|
| CAS # |
787549-23-9
|
| PubChem CID |
11249040
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
5.644
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
35
|
| Complexity |
837
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)NCCCC[C@@H](C(=O)NC1=CC2=C(C=C1)C(=CC(=O)O2)C(F)(F)F)NC(=O)OC(C)(C)C
|
| InChi Key |
NVKNRJCOVHAZDK-KRWDZBQOSA-N
|
| InChi Code |
InChI=1S/C23H28F3N3O6/c1-13(30)27-10-6-5-7-17(29-21(33)35-22(2,3)4)20(32)28-14-8-9-15-16(23(24,25)26)12-19(31)34-18(15)11-14/h8-9,11-12,17H,5-7,10H2,1-4H3,(H,27,30)(H,28,32)(H,29,33)/t17-/m0/s1
|
| Chemical Name |
tert-butyl N-[(2S)-6-acetamido-1-oxo-1-[[2-oxo-4-(trifluoromethyl)chromen-7-yl]amino]hexan-2-yl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0021 mL | 10.0104 mL | 20.0208 mL | |
| 5 mM | 0.4004 mL | 2.0021 mL | 4.0042 mL | |
| 10 mM | 0.2002 mL | 1.0010 mL | 2.0021 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
